52,975 Shares in Dyne Therapeutics, Inc. $DYN Purchased by Flputnam Investment Management Co.

Flputnam Investment Management Co. bought a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 52,975 shares of the company’s stock, valued at approximately $1,177,000.

A number of other hedge funds also recently modified their holdings of DYN. T. Rowe Price Investment Management Inc. increased its position in Dyne Therapeutics by 523.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after buying an additional 14,727,667 shares during the last quarter. BlackRock Inc. purchased a new stake in Dyne Therapeutics in the 2nd quarter worth about $275,500,000. Jupiter Topco LLC purchased a new stake in Dyne Therapeutics during the second quarter valued at about $266,634,000. Vanguard Group Inc. raised its position in shares of Dyne Therapeutics by 14.9% in the fourth quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock valued at $219,376,000 after purchasing an additional 1,455,151 shares during the period. Finally, State Street Corp lifted its stake in shares of Dyne Therapeutics by 27.0% during the 4th quarter. State Street Corp now owns 6,692,745 shares of the company’s stock valued at $130,910,000 after buying an additional 1,423,828 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

DYN stock opened at $25.07 on Monday. The company’s 50 day moving average is $24.37 and its 200 day moving average is $20.08. The stock has a market cap of $4.68 billion, a price-to-earnings ratio of -7.53 and a beta of 1.07. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. Dyne Therapeutics, Inc. has a 1-year low of $11.92 and a 1-year high of $27.31.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). Sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.47 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a research note on Friday, May 15th. Wall Street Zen cut Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Cantor Fitzgerald assumed coverage on Dyne Therapeutics in a research note on Thursday, July 23rd. They set an “overweight” rating on the stock. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Monday, August 17th. Finally, TD Cowen started coverage on Dyne Therapeutics in a research note on Friday, June 26th. They issued a “buy” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $34.42.

Insiders Place Their Bets

In other Dyne Therapeutics news, CFO Erick Lucera sold 2,362 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total transaction of $48,113.94. Following the completion of the sale, the chief financial officer owned 121,563 shares of the company’s stock, valued at $2,476,238.31. This represents a 1.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jason P. Rhodes sold 2,160,516 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the transaction, the director owned 428,946 shares in the company, valued at $10,723,650. The trade was a 83.43% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,139,196 shares of company stock valued at $99,449,852 in the last ninety days. 9.46% of the stock is owned by corporate insiders.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.